Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
FDA Approval of Dupilumab for Uncontrolled COPD will Change the Treatment Landscape
The US FDA approves dupilumab (Dupixent) as an add-on maintenance treatment for adults with uncontrolled COPD and type 2 inflammation, marking the first targeted therapy for the condition in over a decade. Surya Bhatt, MD, MSPH, co-principal investigator of the pivotal phase 3 BOREAS and NOTUS trials, discusses the potential impact on COPD treatment.
Lilly Is Not 'Feeling the Bern' on Drug Prices Like Novo: Why the Double Standard?
Sen. Bernie Sanders and Novo Nordisk CEO Lars Fruergaard Jørgensen clashed over U.S. prices for Ozempic and Wegovy, with Sanders questioning why Novo is targeted while Eli Lilly is not. Sanders' office did not respond to inquiries about potential investigations into Lilly's pricing.
Dupixent approved in the US as the first-ever biologic medicine for patients ...
Dupixent approved by FDA as first biologic for COPD patients with eosinophilic phenotype, based on phase 3 studies showing significant reduction in exacerbations, improved lung function, and quality of life.
Dupixent® (dupilumab) Approved in the U.S. as the
FDA approves Dupixent for adults with inadequately controlled COPD and an eosinophilic phenotype, based on Phase 3 trials showing significant reduction in exacerbations, improved lung function, and quality of life.
First-Ever Biologic Approved for COPD
The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with inadequately controlled COPD with an eosinophilic phenotype. Dupilumab, an IL-4 and IL-13 pathway inhibitor, demonstrated a reduction in annual exacerbations in phase III trials BOREAS and NOTUS. It also improved quality of life and lung function. Common adverse events included viral infection, headache, and nasopharyngitis.
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients
Dupixent approved by FDA as add-on treatment for adults with inadequately controlled COPD and eosinophilic phenotype, based on Phase 3 trials showing significant reduction in exacerbations, improvements in lung function and quality of life.
Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD
The FDA approves Dupixent as the first biologic for COPD patients with an eosinophilic phenotype, based on phase 3 studies showing reduced exacerbations and improved lung function.
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
FDA approves Sanofi and Regeneron’s Dupixent for chronic lung disease, expected to boost sales to over $21 billion by 2030.
Dupixent approved in China as the first-ever
Dupixent approved in China for COPD, based on phase 3 studies showing reduced exacerbations, improved lung function, and quality of life. COPD is a priority in China's Healthy China 2030 plan.
Sanofi/Regeneron's Dupixent set to dominate COPD biologics market following FDA approval
FDA approves Sanofi and Regeneron's Dupixent for uncontrolled COPD, showing significant reduction in exacerbations and improved lung function. Dupixent expected to lead COPD biologics market with projected sales of $6.57bn by 2033.
© Copyright 2025. All Rights Reserved by MedPath